Predicta Biosciences: Valuation, Funding & Investors
Predicta Biosciences is a precision oncology company focused on developing innovative diagnostic and therapeutic products. The company specializes in non-invasive diagnostics for blood cancers, particularly multiple myeloma, enabling physicians to assess the likelihood of patient response to immunotherapies. Founded by experts in cancer genomics, Predicta aims to address unmet needs in the diagnosis and prognosis of blood cancers and autoimmune diseases.
Leadership & Board
Latest Estimated Valuation
- Total Amount Raised
- $23M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $23M
- Latest Funding Round
- Series A
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 08, 2025 | Series A | $23.40M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Mass General Brigham Ventures | Series A |
| Engine Ventures | Series A |
| Lightchain Capital | Series A |
| Illumina Ventures | Series A |
| ACS BrightEdge | Series A |
| Binney Street Capital of Dana-Farber Cancer Institute | Series A |
| Myeloma Solutions Fund | Series A |
Similar Companies
A snapshot of private companies similar to Predicta Biosciences, helping you discover and navigate related company profiles.
Related News and Analysis








